Table 2.
(A) Left ventricular function, remodelling and scar size assessment by MRI. (B) Comparison of MRI parameters between ATV groups
| A | Total RA (n=39) |
Total IA (n=37) |
Total placebo (n=36) |
Total MNCs (n=40) |
| LVEF | ||||
| Baseline | 36.0 (33.0,39.4) | 32.0 (31.0,34.4) | 33.5 (31.5,35.0) | 34.2 (32.7,36.5) |
| Endpoint | 44.0 (41.0,46.5) | 43.0 (39.0,46.0) | 39.5 (37.0,43.3) | 46.0 (44.0,49.5)* |
| Adjusted difference† (95% CI) | 6.9 (4.0 to 9.0) | 10.0 (7.6 to 12.1) | 5.0 (3.5 to 9.2) | 10.0 (8.0 to 12.6) |
| P value | 0.089 | 0.01 | ||
| EDVi (mL/m2) | ||||
| Baseline | 81.5 (74.4,89.7) | 82.2 (75.0,91.0) | 81.9 (74.4,89.7) | 81.8 (73.2,90.0) |
| Endpoint | 67.9 (62.0,75.6) | 71.0 (63.7,81.9) | 72.3 (62.5,78.1) | 68.5 (64.6,78.3) |
| Adjusted difference† (95% CI) | −7.8 (–18.8 to –3.0) | −21.4 (–24.4 to –3.2) | −6.9 (–17.1 to –1.7) | −9.2 (–18.0 to –0.9) |
| P value | 0.718 | 0.832 | ||
| ESVi (mL/m2) | ||||
| Baseline | 49.8 (46.6,61.0) | 55.7 (51.0,61.0) | 50.4 (47.0,60.5) | 55.6 (49.3,62.4) |
| Endpoint | 39.0 (32.0,44.0) | 37.0 (32.0,45.0) | 37.0 (32.5,45.0) | 39.0 (32.0,44.2) |
| Adjusted difference† (95% CI) | −9.7 (–12.2 to –0.8) | −11.2 (–29.9 to –0.7) | −8.1 (–21.4 to –1.2) | −18.5 (–26.3 to –6.1) |
| P value | 0.533 | 0.234 | ||
| Scar size (mm3) | ||||
| Baseline | 39.2 (31.8,42.0) | 41.5 (33.0,44.8) | 39.2 (32.4,43.9) | 40.0 (32.7,42.2) |
| Endpoint | 40.2 (35.7,44.5) | 35.9 (33.0,43.8) | 38.6 (34.6,50.1) | 36.5 (31.0,42.0)‡ |
| Adjusted difference† (95% CI) | 1.67 (–0.16 to 4.80) | 0.81 (–3.32 to 2.62) | 2.60 (1.18 to 6.94) | −2.65 (–5.10 to 1.60) |
| P value | 0.659 | 0.01 | ||
| B | Total RA (n=39) | Total IA (n=37) | ||
| RA+placebo (n=19) | RA+MNCs (n=20) | IA+placebo (n=17) | IA+MNCs (n=20) | |
| LVEF | ||||
| Baseline | 37.8 (29.7,40.7) | 35.5 (33.0,38.8) | 32.5 (30.4,34.7) | 31.6 (29.0,36.0) |
| Endpoint | 43.6 (37.0,46.5) | 45.5 (41.1,49.5) | 38.0 (34.0,41.0) | 47.5 (45.0,52.6)§ |
| Adjusted difference† (95% CI) | 3.4 (0.3 to 12.6) | 7.8 (6.3 to 10.0) | 5.0 (4.0 to 10.0) | 12.6 (10.4 to 19.3) |
| P value | 0.809 | 0.001 | ||
| EDVi (mL/m2) | ||||
| Baseline | 81.5 (74.4,92.1) | 82.5 (67.5,92.7) | 82.2 (73.5,101.0) | 81.8 (73.2,92.6) |
| Endpoint | 71.8 (61.1,75.6) | 67.1 (61.0,79.4) | 76.0 (59.6,94.0) | 70.3 (65.0,81.9) |
| Adjusted difference† (95% CI) | −3.3 (–13.2 to 0.8) | −11.5 (–25.4 to –2.4) | −8.3 (–18.6 to 4.4) | −8.4 (–16.4 to –0.19) |
| P value | 0.799 | 0.987 | ||
| ESVi (mL/m2) | ||||
| Baseline | 49.1 (45.0,63.0) | 52.9 (41.0,65.5) | 54.1 (43.7,61.0) | 56.0 (49.5,67.4) |
| Endpoint | 36.5 (31.0,47.0) | 39.1 (29.5,44.1) | 37.0 (29.2,61.0) | 38.0 (30.2,47.9) |
| Adjusted difference† (95% CI) | −4.5 (−8.5 to 0.7) | −17.5 (−27.8 to –6.1) | −21.4 (−24.3 to 1.4) | −21.1 (−30.1 to –2.0) |
| P value | 0.556 | 0.290 | ||
| Scar size (mm3) | ||||
| Baseline | 39.3 (30.5,47.9) | 39.1 (30.3,45.4) | 33.8 (31.8,47.8) | 41.6 (32.3,49.7) |
| Endpoint | 40.2 (33.0,51.1) | 40.0 (31.4,43.7) | 36.8 (33.8,55.4) | 34.6 (28.0,41.2) |
| Adjusted difference† (95% CI) | 2.06 (0.64 to 8.13) | −1.18 (−4.64 to 3.77) | 3.06 (0.81 to 11.59) | −3.13 (−5.63 to 1.13) |
| P value | 0.161 | 0.026 | ||
*Endpoint values in total MNCs group vs total placebo group (p=0.009).
†Values are median (95% CI), and adjusted for values at baseline and the other intervention.
‡Endpoint values in total MNCs group vs total placebo group (p=0.008).
§The comparison of endpoint values in IA+ MNCs group vs IA+placebo group (p=0.001).
ATV, atorvastatin; EDVi, end-diastolic volume index; ESVi, end-systolic volume index; IA, intensive atorvastatin; LVEF, left ventricular ejection fraction; MNCs, mononuclear cells; RA, regular atorvastatin.